Pieber TR, Bajaj HS, Heller SR, et al. - Based on findings of this post hoc analysis of the CONCLUDE trial, it can be inferred that degludec affords a well-tolerated as well as an efficacious treatment choice for people with type 2 diabetes (T2D) and kidney impairment.

• In the CONCLUDE trial, degludec U200 (degludec) and glargine U300 impacts on hypoglycemia were inquired in adults with basal insulin-treated T2D who had at least one risk criterion for hypoglycemia, one of which was moderate chronic kidney disease (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73m ² ).

• Here, mean alteration in rates of overall symptomatic, nocturnal symptomatic and severe hypoglycemia were assessed during 36-week maintenance span, glycated hemoglobin (HbA1c) from baseline to end of treatment (EOT) and EOT total daily insulin dose, stratified by baseline eGFR.

• Rate ratios for hypoglycemia were found to be consistent with the primary analyses across kidney impairment subgroups.

• Regardless of renal function, a small but consistent greater decrease in HbA1c from baseline as well as a lower total daily insulin dose with degludec vs glargine U300 was evident.